Genfit SA (GNFT) FinancialsGNFTFinancialGenfit SA

Genfit SA (GNFT) generates its revenue primarily from R&D of Innovative Medicines & Diagnostic Solutions, which accounts for 100.0% of total sales, equivalent to €22.80M. Understanding this concentration is critical for investors evaluating how GNFT navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Genfit SA maintains a gross margin of 96.52%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 0.18%, while the net margin is -27.91%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively GNFT converts its operational activities into shareholder value.

In the context of the broader market, GNFT competes directly with industry leaders such as TNXP and TLSA. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, GNFT's gross margin of 96.52% stands against TNXP's 94.81% and TLSA's N/A. Such benchmarking helps identify whether Genfit SA is trading at a premium or discount relative to its financial performance.